<p>Zhaoke Ophthalmology Limited announced that its Investigational New Drug (IND) application for PAN-90806 eye drops, intended for the treatment of wet (neovascular) age-related macular degeneration (wAMD), has been approved by the National Medical Products Administration (NMPA) of China. Additionally, the company has received marketing authorization from the NMPA for its Epinastine HCl eye drops, a treatment for allergic conjunctivitis. These regulatory milestones were achieved solely by Zhaoke Ophthalmology Ltd. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251124-11925768), on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

06622

<p>Zhaoke Ophthalmology Limited has received NMPA approval for its PAN-90806 IND application for treating wet age-related macular degeneration and marketing authorization for Epinastine HCl eye drops for allergic conjunctivitis. These milestones were achieved independently by the company.</p>

Zhaoke Ophthalmology Wins NMPA Approval for PAN-90806 IND and Epinastine HCl Eye Drop